8/104 sources · 2 publishersUpdated Oct 14, 21:12 UTC
AstraZeneca shares jump over 4% on late‑stage oncology trial data, China approval and $2 bn Summit deal
On 14 Oct 2026 AstraZeneca PLC stock rose about 4 % after positive Phase‑3 results for its oncology drug Datroway and regulatory approval in China. The company also announced a $2 bn equity investment in Summit Therapeutics to secure exposure to the ivonescimab program. Analysts at Nordea and Citi upgraded the stock to Buy and lifted their price targets.
Why it matters
Nordea’s target increase to SEK 1,900 and Citi’s to 18,600 GBp may push the share price higher as funds rebalance (). The $2 bn Summit investment gives AstraZeneca direct upside from a promising oncology pipeline, potentially expanding future revenue ().
Key facts
- 1AstraZeneca stock rose 4.02% on 14 Oct 2026. timothysykes.com
- 2The company reported $58.7 billion in annual revenue. timothysykes.com
- 3Gross margin was 81.9%. timothysykes.com
- 4Datroway received Chinese regulatory approval for triple‑negative breast cancer. timothysykes.com
- 5Datroway is now approved in more than 35 countries. timothysykes.com
- 6AstraZeneca closed a $2 billion equity investment in Summit Therapeutics. timothysykes.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.